Financial Data and Key Metrics Changes - Exodus reported Q3 revenue of $30.3 million, representing a 51% year-over-year growth, driven by higher digital asset prices and increased consumer and industry partner engagement [3][9] - Q3 swap volume reached $1.75 billion, an 82% increase from the prior year, with B2B swaps contributing $496 million, accounting for 28% of the quarterly volume [9] - Non-exchange-related revenue exceeded 10% of total revenue for the first time, primarily due to improvements in staking, particularly in Solana staking [9][10] - Monthly active users remained at 1.5 million, a 6% decrease year-over-year, while quarterly funded users increased to 1.8 million, up 20% from a year ago [10][11] - Digital and liquid assets totaled $315 million, with Exodus maintaining a debt-free position and increasing its Bitcoin holdings to 2,123 Bitcoin [11] Business Line Data and Key Metrics Changes - The acquisition of Grateful is expected to enhance Exodus's payment strategy, providing tools for merchant checkout experiences based on stablecoins [4][11] - The company has signed 16 partnerships in the industry, with 10 already producing results, indicating growing traction in its traditional crypto business and XO Swap [5][9] Market Data and Key Metrics Changes - The overall economic environment for the quarter was supported by rising prices of Bitcoin and Ethereum, with stablecoin and real-world asset tokenization adoption seen as key future catalysts [7][8] Company Strategy and Development Direction - Exodus aims to evolve beyond a crypto wallet, positioning itself as a comprehensive financial app for payments and money transfers, leveraging stablecoins for transactions [3][4] - The company is exploring the potential for a Bitcoin dividend to reward shareholders and promote the adoption of its products [12][13] - The integration of Grateful is seen as a strategic move to penetrate the traditional payment space and enhance the user experience across jurisdictions [11][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the significant opportunity in Latin America for stablecoin-based payments, particularly in countries with high inflation like Argentina [28][34] - The focus is on creating a seamless user experience that integrates various financial services within a single app, catering to the preferences of younger generations [34][36] Other Important Information - The Grateful acquisition was a mix of cash and stock, with the financial impact expected to be modest but significant in terms of technology and market reach [18][19] - The company is actively pursuing a charter amendment to allow for the potential issuance of Bitcoin dividends to Class A stockholders [14] Q&A Session Summary Question: Can you elaborate on the Grateful acquisition and its integration timeline? - The Grateful acquisition is set to go live next month in Uruguay, focusing on merchant services and checkout experiences [17] Question: What is the monetization model for Grateful? - The short-term focus is on utility rather than immediate monetization, with potential for consumer services like loans and yield generation from stablecoins [25][26] Question: How significant is the opportunity in Latin America for stablecoin payments? - The opportunity is described as huge, particularly in high-inflation countries like Argentina, where stablecoins are in demand [28] Question: How will Exodus incentivize users to adopt its platform? - The strategy includes integrating with credit and debit cards, providing a seamless experience for users to manage their assets in one app [34][36]

Financial Data and Key Metrics Changes - Net contribution increased by 28% year over year to $215 million, while adjusted EBITDA rose by 43% to $78 million, resulting in solid operating margins of 36% [3][22] - Assets under administration reached a record high of $20.8 billion, up 76% year over year, and funded accounts grew by 16% to 3.73 million [6][22] Business Line Data and Key Metrics Changes - Net trading contribution from crypto surged by 229% year over year to $56 million, driven by higher invested amounts per trade and increased activity [23] - Net trading contribution from capital markets, equities, commodities, and currencies declined by 21% year over year to $73 million due to a shift in investor activity towards crypto [23] - Net interest income increased by 44% year over year to $62 million, attributed to a 52% rise in higher interest-earning assets [23] Market Data and Key Metrics Changes - Funded accounts in October grew by 17% year over year to 3.76 million, while assets under administration were $20.5 billion, up 72% year over year [26] - The US market saw a threefold increase in crypto volumes quarter over quarter, following the expansion of the crypto offering [16][17] Company Strategy and Development Direction - The company is focused on expanding into new frontiers in crypto, tokenization, and AI, while broadening its global reach [4][12] - Strategic pillars include trading, investing, wealth management, and neobanking, with ongoing product innovation [6][12] - A $150 million share repurchase program was announced, reflecting confidence in long-term growth prospects [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit growth in funded accounts, driven by the transition of younger generations into investing [19][51] - The company aims to maintain leadership in Europe while expanding aggressively in the US and Asia [46][47] Other Important Information - The company launched a new subscription model for the eToro Club, providing premium benefits and exclusive features [28] - The integration of Spaceship in Australia allows users direct access to superannuation products [10] Q&A Session Summary Question: Why did eToro launch the new subscription offering? - The eToro Club program was designed to provide premium benefits and consolidate previous subscription models, enhancing user engagement [28][29] Question: Can you discuss account growth and regional contributions? - Account growth has been strong, with double-digit growth observed, particularly from new regions and core markets [31][34] Question: What are the implications of artificial intelligence for trading? - AI tools are being developed to enhance user engagement and automate trading strategies, with a focus on increasing trade frequency [39][40] Question: How does eToro plan to scale copy trading in the US? - The strategy involves promoting copy trading within the app and increasing the number of top investors for users to copy [70][72] Question: What are the capital allocation priorities? - The company is focused on share buybacks and exploring acquisition opportunities to drive growth [62][63] Question: How does eToro view banking services in the long term? - The company aims to position itself as a financial super app, enhancing customer engagement through banking services and investment tools [91][92]

Financial Data and Key Metrics Changes - As of September 30, 2025, the company had approximately $86 million in cash, cash equivalents, short-term bank deposits, and investments in marketable securities [17] - Revenues for Q3 2025 were approximately $1.9 million, a significant decrease from approximately $17.1 million in Q3 2024 [17] - R&D expenses for Q3 2025 were approximately $5.8 million, down from approximately $6.3 million in Q3 2024 [18] - The net loss for Q3 2025 was approximately $6.98 million, or $0.07 per share, compared to a net profit of approximately $1.28 million, or $0.01 per share in Q3 2024 [18] Business Line Data and Key Metrics Changes - The company is advancing its COM701 trial for platinum-sensitive ovarian cancer, with ongoing efforts to support the Maya ovarian platform trial [12][14] - COM902 is highlighted as one of the only two clinical-stage FC-reduced anti-TIGIT monoclonal antibodies currently in development, fully owned by the company [8] Market Data and Key Metrics Changes - The potential commercial opportunity for Rilvegostomig, a bispecific antibody, is substantial, with AstraZeneca estimating peak year revenue targets of over $5 billion [9] - The company is eligible for regulatory and commercial milestones and tiered royalties from AstraZeneca's broad development program, which includes 11 phase III trials across various cancers [10] Company Strategy and Development Direction - The company emphasizes its pioneering role in computational drug target discovery and aims to leverage its expertise in digital biology to deliver significant patient value [4] - The strategy includes focusing on FC-reduced formats for anti-TIGIT antibodies, with COM902 positioned to capture market interest as new data emerges [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing trials and the potential for COM701 and COM902 to address significant unmet medical needs [12][14] - The company anticipates that the cash runway will support operations into Q3 2027, allowing continued investment in clinical trials and early-stage pipeline development [17] Other Important Information - The company presented a pooled analysis of COM701 at ESMO, demonstrating its clinical benefit in patients with heavily pretreated platinum-resistant ovarian cancer [12][13] - The Maya ovarian platform trial is progressing, with sites activated across the US, Israel, and France, and an interim analysis expected in Q1 2027 [14] Q&A Session Summary Question: What factors influenced the extension of the Maya interim analysis to Q1 2027? - Management indicated that the extension is due to site openings, enrollment rates, and the accumulation of events in the trial [20][22] Question: What are the expectations for the upcoming Arcus-Gilead readout with their TIGIT in gastric cancer? - Management noted that the readout could validate their hypotheses regarding FC-reduced TIGIT antibodies, but emphasized that it is only one trial among many [28][30] Question: What internal thresholds are being considered for the interim update from the Maya ovarian trial? - The company is looking for a clinically meaningful improvement of up to three months above placebo in the trial [35][38] Question: Can COM902 be partnered with another company despite the license agreement with AstraZeneca? - Management confirmed that they fully own COM902 and have no restrictions on pursuing partnerships, allowing for opportunistic decisions based on market developments [42][43] Question: How does the tolerability profile of COM701 influence its use in combination therapies? - Management stated that COM701 is extremely well tolerated as a monotherapy, which supports its potential use in combination therapies [46][47]

Financial Data and Key Metrics Changes - Net revenue for Q3 2025 was $821.5 million, reflecting a 6.6% year-over-year increase [4][17] - Adjusted EBITDA was $136.4 million, up 6.1% year-over-year, with an adjusted EBITDA margin of 16.6% [4][17] - Same facility revenue grew by 6.3%, with same facility case growth of 3.4% and rate growth of 2.8% [17][22] Business Line Data and Key Metrics Changes - Over 166,000 surgical cases were performed in Q3, representing a 2.1% growth, with significant increases in GI and MSK procedures [5][17] - Total joint surgeries in ASC facilities grew by 16% in Q3 and 23% year-to-date compared to the same period last year [5][17] - The payer mix showed commercial payers at 50.6% of revenues, down 160 basis points year-over-year, while governmental sources increased by 120 basis points [7][17] Market Data and Key Metrics Changes - The company observed softer-than-expected same facility volume growth in recent months, prompting adjustments to the fourth quarter outlook [7][15] - The revised guidance for full-year revenue is now expected to be in the range of $3.275 billion to $3.3 billion [12][21] Company Strategy and Development Direction - The company is focused on three growth pillars: organic growth, margin improvement, and capital deployment for M&A [4] - A strategic portfolio optimization process is underway to enhance flexibility and streamline operations, with a focus on divesting larger surgical hospitals [11][12] - The company plans to open two new DeNovo facilities in Q3, with nine under construction and more than a dozen in the development pipeline, primarily targeting higher acuity specialties [9][10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged recent trends in surgical demand and payer mix, particularly among commercial patients, which have led to a more cautious outlook for Q4 [15][22] - The company remains confident in its long-term growth algorithm and the resilience of its business model despite near-term challenges [15][22] Other Important Information - The company has deployed approximately $71 million in capital for acquisitions in 2025 and anticipates a return to normal levels of annual capital investment moving into 2026 [8][9] - The cash balance at the end of the quarter was $203.4 million, with total available liquidity exceeding $600 million [18] Q&A Session Summary Question: What is causing the weakness in demand or procedure volumes as you think through Q4? - Management noted broad-based weakness in volumes and payer mix, with higher government payer mix than expected entering Q4, but still anticipates growth in cases and rates [24][25] Question: Is the low level of spend on acquisitions due to deal timing or evaluation? - Management confirmed strong deal flow but emphasized a disciplined approach to acquisitions, indicating that timing is a factor [26] Question: Can you elaborate on the payer mix commentary? - Management indicated that while there is always pressure from payers, the current issue is more about a weaker growth trend rather than systematic problems [30][31] Question: How do you expect free cash flow to land in Q4 and the year ahead? - Management refrained from providing specific guidance on free cash flow but noted strong operating cash flow and improvements in working capital [76][80] Question: What are the implications of the portfolio review process? - Management is focused on optimizing the portfolio to enhance cash flow and reduce leverage, with potential partnerships or divestitures being considered [55][60]

Financial Data and Key Metrics Changes - Net revenue for Q3 2025 was $821.5 million, reflecting a year-over-year increase of 6.6% [4][17] - Adjusted EBITDA for the quarter was $136.4 million, up 6.1% year-over-year, with an adjusted EBITDA margin of 16.6% [4][17] - Same facility revenue grew by 6.3%, with same facility case growth of 3.4% and rate growth of 2.8% [17][22] Business Line Data and Key Metrics Changes - Over 166,000 surgical cases were performed in Q3, representing a 2.1% growth, with significant increases in GI and MSK procedures [5][17] - Total joint surgeries in ASC facilities grew by 16% in Q3 and 23% year-to-date compared to the same period last year [5][17] - The payer mix showed commercial payers at 50.6% of revenues, down 160 basis points year-over-year, while governmental sources increased by 120 basis points [7] Market Data and Key Metrics Changes - The company observed softer-than-expected same facility volume growth in recent months, prompting adjustments to the fourth quarter outlook [7][15] - The revised guidance for full-year revenue is now expected to be in the range of $3.275 billion to $3.3 billion, with adjusted EBITDA between $535 million and $540 million [12][21] Company Strategy and Development Direction - The company is focused on three growth pillars: organic growth, margin improvement, and capital deployment for M&A [4] - A strategic portfolio optimization review is underway to enhance flexibility and streamline operations, with a focus on divesting larger surgical hospitals that do not align with the core ASC service lines [10][11] - The company plans to open two new de novo facilities in Q3, with nine under construction and more than a dozen in the development pipeline, primarily targeting higher acuity specialties [9][21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged recent trends in surgical demand and payer mix, particularly among commercial patients, and is taking a cautious approach heading into Q4 [15][22] - The company remains confident in its long-term growth algorithm and the resilience of its business model despite near-term challenges [15][22] - Management emphasized the importance of disciplined capital employment and operational excellence for sustainable growth beyond 2025 [15] Other Important Information - The company has deployed approximately $71 million in capital for acquisitions in 2025 and anticipates a robust M&A pipeline with over $300 million in opportunities under evaluation [8][9] - The cash balance at the end of Q3 was $203.4 million, with total available liquidity exceeding $600 million [18] Q&A Session Summary Question: What is causing the weakness in demand or procedure volumes as you think through Q4? - Management noted broad-based weakness in volumes and payer mix, with higher government payer mix than expected entering Q4, but still anticipates growth in cases and rates [24][25] Question: Is the low level of spend on acquisitions due to deal timing or evaluation? - Management confirmed strong deal flow and a disciplined approach to acquisitions, indicating that timing is a factor but they expect to return to normal M&A flow [26] Question: Can you clarify the payer mix commentary regarding commercial volumes? - Management indicated that while there is always pressure from payers, the current issue is not due to systematic changes but rather a weaker growth trend than expected [30][31] Question: How do you expect free cash flow to land in Q4 and the year ahead? - Management refrained from providing specific guidance on free cash flow but indicated strong operating cash flow and improvements in working capital [76][80] Question: What are the expectations for de novo facilities going into next year? - Management expressed excitement about de novo opportunities, emphasizing that they are primarily focused on higher acuity facilities and have a strong pipeline [46][48]

Financial Data and Key Metrics Changes - As of September 30, 2025, the company had approximately $86 million in cash, cash equivalents, short-term bank deposits, and investments in marketable securities [17] - Revenues for Q3 2025 were approximately $1.9 million, a significant decrease from approximately $17.1 million in Q3 2024 [17] - R&D expenses for Q3 2025 were approximately $5.8 million, down from approximately $6.3 million in Q3 2024 [18] - The net loss for Q3 2025 was approximately $6.98 million, or $0.07 per share, compared to a net profit of approximately $1.28 million, or $0.01 per share in Q3 2024 [18] Business Line Data and Key Metrics Changes - The company is advancing its COM701 trial for platinum-sensitive ovarian cancer and GS0321 in the clinic, with a focus on early-stage pipeline investments [17][15] - COM902 is highlighted as one of the only two clinical-stage FC-reduced anti-TIGIT monoclonal antibodies currently in development, fully owned by the company [8] Market Data and Key Metrics Changes - The potential commercial opportunity for Rilvegostomig, a bispecific antibody, is estimated to exceed $5 billion in peak year revenue [9] - The ongoing Maya ovarian platform trial is expected to address a significant unmet need for maintenance therapy in platinum-sensitive ovarian cancer [14] Company Strategy and Development Direction - The company emphasizes its pioneering role in computational drug target discovery and aims to leverage its expertise in digital biology to deliver significant patient value [4] - The strategy includes focusing on FC-reduced formats, with COM902 and COM701 positioned as key assets [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical momentum of their programs and the potential for improved safety profiles with FC-reduced formats [7][8] - The company anticipates cash runway to support operations into Q3 2027, allowing continued investment in key trials [17] Other Important Information - The company presented a pooled analysis of COM701 at ESMO, demonstrating well-tolerated results and durable responses in patients with heavily pretreated platinum-resistant ovarian cancer [12][13] - The interim analysis for the Maya trial is now estimated for Q1 2027, reflecting adjustments based on enrollment and event accumulation [25] Q&A Session Summary Question: What is the reason for the delay in the Maya interim analysis? - Management indicated that the delay is due to factors such as site openings, enrollment rates, and event accumulation, with most sites now activated [22][24] Question: What are the expectations for the upcoming Arcus-Gilead readout? - Management noted that the readout will be significant for validating their hypotheses regarding FC-reduced TIGIT antibodies, regardless of the outcome [29][30] Question: What internal thresholds are being considered for the interim update from Maya ovarian? - The company is looking for a clinically meaningful improvement of up to three months above placebo in the interim analysis [38] Question: Are there any restrictions on partnering COM902? - Management confirmed that there are no restrictions on COM902, allowing for flexibility in potential partnerships [43] Question: How does the tolerability profile of COM701 influence its use in combination therapies? - Management stated that COM701 is extremely well tolerated as a monotherapy, which supports its use in combination therapies [46]

Financial Data and Key Metrics Changes - Net contribution increased by 28% year over year to $215 million, while adjusted EBITDA rose by 43% to $78 million, resulting in solid operating margins of 36% [3][22] - Assets under administration reached a record high of $20.8 billion, up 76% year over year, and funded accounts grew by 16% to 3.73 million [6][22] Business Line Data and Key Metrics Changes - Net trading contribution from crypto surged by 229% year over year to $56 million, driven by higher invested amounts per trade and increased activity [23] - Net trading contribution from capital markets, equities, commodities, and currencies declined by 21% year over year to $73 million due to a shift in investor activity towards crypto [23] - Net interest income increased by 44% year over year to $62 million, largely due to a 52% rise in higher interest-earning assets [23] Market Data and Key Metrics Changes - Funded accounts in October reached 3.76 million, up 17% year over year, while assets under administration were $20.5 billion, reflecting a 72% year-over-year increase [26][27] Company Strategy and Development Direction - The company is focused on expanding into new frontiers in crypto, tokenization, and AI, while broadening its global reach [4][12] - The strategic pillars include trading, investing, wealth management, and neobanking, with ongoing product innovation [6][12] - The company aims to democratize investing by making it simple, accessible, and social, while enhancing user engagement through AI-driven tools [6][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustainable, profitable growth, driven by innovation and market expansion [20][21] - The company anticipates significant growth opportunities from younger generations entering the market, with a focus on digital-first engagement [19][20] Other Important Information - A $150 million share repurchase program was announced, reflecting confidence in long-term growth prospects and commitment to shareholder value [20] - The company is exploring M&A opportunities to drive inorganic growth while maintaining a disciplined approach [21] Q&A Session Summary Question: Why did eToro launch the new subscription offering? - The subscription model was designed to provide premium benefits and consolidate previous models, enhancing user engagement [28][29] Question: Can you discuss account growth and regional contributions? - Account growth has been strong, with early positive signs from new regions and significant strength in core markets [31][34] Question: What are the implications of AI for trading and engagement? - AI tools are expected to enhance user engagement and trading frequency, with a focus on automating strategies [39][40] Question: How does eToro view its strategic focus by geography? - The company aims for long-term growth in the U.S. and Asia while maintaining leadership in Europe through data-driven marketing [45][47] Question: What is the outlook for account growth going forward? - The company aims for double-digit growth in funded accounts, supported by a strong market and product offerings [50][51] Question: Can you elaborate on the strong crypto volumes and their impact? - Strong crypto activity was noted, with a shift in trading dynamics affecting capital markets revenues [54][56] Question: What are the capital allocation priorities? - The company is focused on share buybacks and exploring acquisition opportunities to enhance growth [62][63] Question: How does eToro view banking services in the long term? - The company sees banking as part of a broader strategy to enhance customer engagement and increase share of wallet [90][92]

Financial Data and Key Metrics Changes - Exodus reported Q3 2025 revenue of $30.3 million, representing a 51% year-over-year growth, driven by higher digital asset prices [4][11] - Q3 swap volume reached $1.75 billion, an increase of 82% from the prior year, with B2B swaps contributing $496 million, accounting for 28% of the quarterly volume [11] - Non-exchange-related revenue increased to over 10% of total revenue for the first time, primarily due to improvements in staking, particularly in Solana staking [11][12] - Monthly active users stood at 1.5 million, a 6% decrease year-over-year, while quarterly funded users increased to 1.8 million, up 20% from a year ago [12] Business Line Data and Key Metrics Changes - The acquisition of Grateful is expected to enhance Exodus' payment strategy, providing tools for merchant checkout experiences based on stablecoins [5][12] - Exodus has signed 16 partnerships in the industry, with 10 already producing revenue, indicating growth in its traditional crypto business and ExoSwap [6][12] Market Data and Key Metrics Changes - The company served 37% of exchange provider volume to ExoSwap industry partners in September, up from 26% in the previous month [6] - The price of Bitcoin and Ethereum supported the overall economic environment for the quarter, with stablecoin and real-world asset tokenization adoption seen as key future catalysts [9][10] Company Strategy and Development Direction - Exodus aims to become a comprehensive financial app, integrating payments, investments, and savings, moving beyond just a crypto wallet [4][10] - The company is exploring a Bitcoin dividend for shareholders, which could leverage a core asset to reward stockholders and promote product adoption [14][15] - The Grateful acquisition is part of a broader strategy to enhance capabilities in the traditional payment space and expand into new regions [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential of stablecoins and the importance of integrating Grateful into their platform [5][9] - The company sees significant opportunities in Latin America, particularly in countries like Argentina, where there is a high demand for stablecoin usage due to inflation [29] Other Important Information - Exodus maintains a debt-free position with digital and liquid assets totaling $315 million as of September 30, including 2,123 Bitcoin [13] - The company is actively pursuing a charter amendment to allow for Bitcoin dividends, which is subject to board approval [15] Q&A Session Summary Question: Can you unpack the Grateful acquisition and its integration timeline? - Management confirmed that Grateful will go live next month in Uruguay, focusing on merchant services and checkout experiences [19][20] Question: What does the monetization model for Grateful look like? - The focus is on utility for merchants rather than immediate monetization, with potential for consumer services like loans and yield from stablecoins [27][28] Question: How significant is the opportunity in Latin America for stablecoin payments? - Management highlighted the vast potential in Latin America, especially in Argentina, where stablecoins are in high demand due to economic conditions [29] Question: How will Exodus incentivize users to adopt their platform? - The strategy includes integrating with credit and debit cards, providing a seamless experience for users to manage various assets in one app [35][37]

Financial Data and Key Metrics Changes - Consolidated net sales increased by 21% year over year in Q3, reaching $66.7 million, driven by growth in the Canadian cannabis segment and contributions from recreational cannabis sales in the Netherlands [4][17] - Net income from continuing operations was $10.8 million, or $0.09 per share, an increase of nearly 10% sequentially compared to the previous quarter [4][17] - Adjusted EBITDA from continuing operations was $20.7 million, resulting in an adjusted EBITDA margin of 31%, compared to 8.5% in Q3 of the previous year [4][17] - Cash flow from operations improved to $24.4 million, compared to $6.1 million in Q3 of the previous year [4][18] Business Line Data and Key Metrics Changes - Canadian cannabis business net sales grew by 29% year over year, reaching CAD 64.1 million, driven by strong performance in targeted channels and improved pricing [5][18] - Canadian cannabis gross margin was 56%, up from 26% in Q3 of the previous year, exceeding the targeted range of 30%-40% [11][19] - Adjusted EBITDA for Canadian cannabis improved by 309% year over year to CAD 26.6 million, resulting in an adjusted EBITDA margin of 41% [11][19] - The Netherlands cannabis operations generated EUR 3.6 million in sales with adjusted EBITDA of EUR 1.3 million, marking significant increases quarter over quarter [12][20] Market Data and Key Metrics Changes - The international medical cannabis business saw over 750% sales growth year over year, with significant contributions from Germany [5][18] - Village Farms is now believed to be the largest exporter of medical cannabis to Europe, with a strong position to expand into new markets [8][9] - Canadian cannabis retail sales were in line with expectations, with stronger contribution margins from retail branded sales [6][18] Company Strategy and Development Direction - The company is focused on scaling its cannabis production capabilities, with a 40 metric ton capacity expansion project underway, expected to increase annual production capacity in Canada by approximately 33% [10][11] - The company aims to continue supporting growth in Canada and abroad, with plans to expand into multiple new international jurisdictions [9][10] - The management emphasizes a culture of cost discipline and continuous improvement to drive future growth [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of positive trends across the business, citing competitive strengths and growth catalysts [4][25] - The company anticipates continued growth in revenue and EBITDA, supported by operational and manufacturing expertise [25] - Management highlighted the importance of consistent product quality and operational excellence in maintaining competitive advantage [30] Other Important Information - The company closed the quarter with approximately $88 million in cash, reflecting an increase of nearly $23 million since the end of Q2 [16][22] - A share repurchase program was implemented as part of a balanced approach to capital allocation to drive shareholder returns [16][23] Q&A Session Summary Question: About cannabis gross margin improvement - Management noted improved efficiency, higher crop yields, favorable pricing, and international export sales as key drivers for the sequential gross margin improvement [26][27] Question: Competitive environment and market share in international markets - Management indicated that consistent high-quality production and EU GMP certification have positioned the company well to gain market share, particularly in Germany [30][34] Question: Performance and outlook for the Netherlands - Management confirmed that long-term gross margin targets for the Netherlands are similar to those for Canadian cannabis, emphasizing the startup nature of the operations [31][32] Question: Regulatory changes and opportunities in Texas - Management expressed excitement about the regulatory changes in Texas and confirmed that they are exploring suitable structures to maintain their NASDAQ listing while considering M&A opportunities [36][37] Question: Quebec's importance and regulatory changes - Management acknowledged Quebec's significance but clarified that it does not account for 40% of total cannabis revenue, while highlighting the potential benefits from recent regulatory changes [38][39] Question: Competitive landscape in the Netherlands - Management noted that while some competitors face challenges, the company is focused on expanding its capacity and is well-positioned for future growth [40]

Financial Data and Key Metrics Changes - Net contribution increased by 28% year over year to $215 million, while adjusted EBITDA rose by 43% to $78 million, resulting in solid operating margins of 36% [3][22] - Assets under administration reached a record high of $20.8 billion, up 76% year over year, and funded accounts grew by 16% to 3.73 million [5][22] Business Line Data and Key Metrics Changes - Net trading contribution from crypto surged by 229% year over year to $56 million, driven by higher invested amounts per trade and increased activity [23] - Net trading contribution from capital markets, equities, commodities, and currencies declined by 21% year over year to $73 million due to a shift in investor activity towards crypto [23] - Net interest income increased by 44% year over year to $62 million, largely due to a 52% rise in higher interest-earning assets [23] Market Data and Key Metrics Changes - Funded accounts in the US saw significant growth, with new funded accounts surpassing those of 2024 year-to-date, and a three-times increase in crypto volumes quarter over quarter [16][17] - The company expanded its market access globally, now offering access to 22 different exchanges and planning to increase to over 30 by 2026 [6] Company Strategy and Development Direction - The company is focused on four strategic pillars: trading, investing, wealth management, and neobanking, while accelerating product innovation [5][11] - Plans to democratize investing by making it simple, accessible, and social, with a focus on AI-driven tools and community engagement [4][12] - A $150 million share repurchase program was announced, reflecting confidence in long-term growth prospects [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capture significant growth opportunities driven by innovation, global expansion, and macro trends [11][19] - The company anticipates continued strong performance in Q4, with positive momentum in capital markets and crypto businesses [25] Other Important Information - The company launched a new subscription model for the eToro Club, providing premium benefits and exclusive features [10][26] - The integration of Spaceship in Australia allows users direct access to superannuation products, enhancing the wealth management offering [10] Q&A Session Summary Question: Comment on the new subscription offering and its opportunity - The subscription model was launched to provide premium benefits and consolidate previous models, enhancing customer engagement [26][27] Question: Discuss account growth and contributing regions - Account growth has been strong, with double-digit growth driven by increased deposits and engagement, though geographic breakdowns were not provided [28][29] Question: Implications of artificial intelligence on trading - AI tools are being developed to enhance user engagement and automate trading strategies, with early signs of success in user adoption [30][31] Question: Strategic focus by geography - The company aims for long-term growth in the US and Asia while maintaining leadership in Europe, focusing on data-driven marketing strategies [33][34] Question: Account growth expectations - The company targets double-digit growth in funded accounts, supported by a growing market of younger investors [35][36] Question: Dynamics of crypto trading volumes - Strong crypto trading volumes were noted, with a shift in investor activity impacting capital markets revenues [37][38] Question: Capital allocation priorities - The company is balancing share buybacks with potential M&A opportunities, maintaining a strong cash position [40][41] Question: Pathway for prediction markets - The company is exploring both organic and inorganic opportunities for prediction markets, leveraging existing infrastructure [42] Question: Mechanics of copy trading in the US - Copy trading operates similarly in the US and internationally, with ongoing enhancements to the Pro Investor program [50][51]